Center-Authored Papers

Filters: Author is Slovak, Marilyn L  [Clear All Filters]
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 
2008
Pullarkat V, Slovak ML, Kopecky KJ, Forman SJ, Appelbaum FR.  2008.  Impact of cytogenetics on the outcome of adult acute lymphoblastic leukemia: results of Southwest Oncology Group 9400 study.. Blood. 111(5):2563-72. Abstract
2010
Advani AS, Gundacker HM, Sala-Torra O, Radich JP, Lai R, Slovak ML, Lancet JE, Coutre SE, Stuart RK, Mims MP et al..  2010.  Southwest Oncology Group Study S0530: a phase 2 trial of clofarabine and cytarabine for relapsed or refractory acute lymphocytic leukaemia.. British journal of haematology. 151(5):430-4. Abstract
Chauncey TR, Gundacker H, Shadman M, List AF, Dakhil SR, Erba HP, Slovak ML, Chen I-M, Willman CL, Kopecky KJ et al..  2010.  Sequential phase II Southwest Oncology Group studies (S0112 and S0301) of daunorubicin and cytarabine by continuous infusion, without and with ciclosporin, in older patients with previously untreated acute myeloid leukaemia.. British journal of haematology. 148(1):48-58. Abstract
2012
Wiernik PH, Sun Z, Gundacker H, Dewald G, Slovak ML, Paietta E, Kim HT, Appelbaum FR, Cassileth PA, Tallman MS.  2012.  Prognostic implications of additional chromosome abnormalities among patients with de novo acute promyelocytic leukemia with t(15;17).. Medical oncology (Northwood, London, England). 29(3):2095-101. Abstract
2013
Erba HP, Othus M, Walter RB, Kirschbaum MH, Tallman MS, Larson RA, Slovak ML, Kopecky KJ, Gundacker HM, Appelbaum FR.  2013.  Four different regimens of farnesyltransferase inhibitor tipifarnib in older, untreated acute myeloid leukemia patients: North American Intergroup Phase II study SWOG S0432.. Leukemia research. Abstract
2014
Deininger MW, Kopecky KJ, Radich JP, Kamel-Reid S, Stock W, Paietta E, Emanuel PD, Tallman M, Wadleigh M, Larson RA et al..  2014.  Imatinib 800 mg daily induces deeper molecular responses than imatinib 400 mg daily: results of SWOG S0325, an intergroup randomized PHASE II trial in newly diagnosed chronic phase chronic myeloid leukaemia.. British journal of haematology. 164(2):223-32. Abstract
Adenine Nucleotides
Advani AS, Gundacker HM, Sala-Torra O, Radich JP, Lai R, Slovak ML, Lancet JE, Coutre SE, Stuart RK, Mims MP et al..  2010.  Southwest Oncology Group Study S0530: a phase 2 trial of clofarabine and cytarabine for relapsed or refractory acute lymphocytic leukaemia.. British journal of haematology. 151(5):430-4. Abstract
Adolescent
Pullarkat V, Slovak ML, Kopecky KJ, Forman SJ, Appelbaum FR.  2008.  Impact of cytogenetics on the outcome of adult acute lymphoblastic leukemia: results of Southwest Oncology Group 9400 study.. Blood. 111(5):2563-72. Abstract
Adult
Pullarkat V, Slovak ML, Kopecky KJ, Forman SJ, Appelbaum FR.  2008.  Impact of cytogenetics on the outcome of adult acute lymphoblastic leukemia: results of Southwest Oncology Group 9400 study.. Blood. 111(5):2563-72. Abstract
Advani AS, Gundacker HM, Sala-Torra O, Radich JP, Lai R, Slovak ML, Lancet JE, Coutre SE, Stuart RK, Mims MP et al..  2010.  Southwest Oncology Group Study S0530: a phase 2 trial of clofarabine and cytarabine for relapsed or refractory acute lymphocytic leukaemia.. British journal of haematology. 151(5):430-4. Abstract
Age Distribution
Pullarkat V, Slovak ML, Kopecky KJ, Forman SJ, Appelbaum FR.  2008.  Impact of cytogenetics on the outcome of adult acute lymphoblastic leukemia: results of Southwest Oncology Group 9400 study.. Blood. 111(5):2563-72. Abstract
Aged
Pullarkat V, Slovak ML, Kopecky KJ, Forman SJ, Appelbaum FR.  2008.  Impact of cytogenetics on the outcome of adult acute lymphoblastic leukemia: results of Southwest Oncology Group 9400 study.. Blood. 111(5):2563-72. Abstract
Chauncey TR, Gundacker H, Shadman M, List AF, Dakhil SR, Erba HP, Slovak ML, Chen I-M, Willman CL, Kopecky KJ et al..  2010.  Sequential phase II Southwest Oncology Group studies (S0112 and S0301) of daunorubicin and cytarabine by continuous infusion, without and with ciclosporin, in older patients with previously untreated acute myeloid leukaemia.. British journal of haematology. 148(1):48-58. Abstract
Aged, 80 and over
Chauncey TR, Gundacker H, Shadman M, List AF, Dakhil SR, Erba HP, Slovak ML, Chen I-M, Willman CL, Kopecky KJ et al..  2010.  Sequential phase II Southwest Oncology Group studies (S0112 and S0301) of daunorubicin and cytarabine by continuous infusion, without and with ciclosporin, in older patients with previously untreated acute myeloid leukaemia.. British journal of haematology. 148(1):48-58. Abstract
Antineoplastic Agents
Pullarkat V, Slovak ML, Kopecky KJ, Forman SJ, Appelbaum FR.  2008.  Impact of cytogenetics on the outcome of adult acute lymphoblastic leukemia: results of Southwest Oncology Group 9400 study.. Blood. 111(5):2563-72. Abstract
Antineoplastic Combined Chemotherapy Protocols
Advani AS, Gundacker HM, Sala-Torra O, Radich JP, Lai R, Slovak ML, Lancet JE, Coutre SE, Stuart RK, Mims MP et al..  2010.  Southwest Oncology Group Study S0530: a phase 2 trial of clofarabine and cytarabine for relapsed or refractory acute lymphocytic leukaemia.. British journal of haematology. 151(5):430-4. Abstract
Pullarkat V, Slovak ML, Kopecky KJ, Forman SJ, Appelbaum FR.  2008.  Impact of cytogenetics on the outcome of adult acute lymphoblastic leukemia: results of Southwest Oncology Group 9400 study.. Blood. 111(5):2563-72. Abstract
Chauncey TR, Gundacker H, Shadman M, List AF, Dakhil SR, Erba HP, Slovak ML, Chen I-M, Willman CL, Kopecky KJ et al..  2010.  Sequential phase II Southwest Oncology Group studies (S0112 and S0301) of daunorubicin and cytarabine by continuous infusion, without and with ciclosporin, in older patients with previously untreated acute myeloid leukaemia.. British journal of haematology. 148(1):48-58. Abstract
Arabinonucleosides
Advani AS, Gundacker HM, Sala-Torra O, Radich JP, Lai R, Slovak ML, Lancet JE, Coutre SE, Stuart RK, Mims MP et al..  2010.  Southwest Oncology Group Study S0530: a phase 2 trial of clofarabine and cytarabine for relapsed or refractory acute lymphocytic leukaemia.. British journal of haematology. 151(5):430-4. Abstract
Center-Authored Paper
Pullarkat V, Slovak ML, Kopecky KJ, Forman SJ, Appelbaum FR.  2008.  Impact of cytogenetics on the outcome of adult acute lymphoblastic leukemia: results of Southwest Oncology Group 9400 study.. Blood. 111(5):2563-72. Abstract
Chauncey TR, Gundacker H, Shadman M, List AF, Dakhil SR, Erba HP, Slovak ML, Chen I-M, Willman CL, Kopecky KJ et al..  2010.  Sequential phase II Southwest Oncology Group studies (S0112 and S0301) of daunorubicin and cytarabine by continuous infusion, without and with ciclosporin, in older patients with previously untreated acute myeloid leukaemia.. British journal of haematology. 148(1):48-58. Abstract
Advani AS, Gundacker HM, Sala-Torra O, Radich JP, Lai R, Slovak ML, Lancet JE, Coutre SE, Stuart RK, Mims MP et al..  2010.  Southwest Oncology Group Study S0530: a phase 2 trial of clofarabine and cytarabine for relapsed or refractory acute lymphocytic leukaemia.. British journal of haematology. 151(5):430-4. Abstract
Wiernik PH, Sun Z, Gundacker H, Dewald G, Slovak ML, Paietta E, Kim HT, Appelbaum FR, Cassileth PA, Tallman MS.  2012.  Prognostic implications of additional chromosome abnormalities among patients with de novo acute promyelocytic leukemia with t(15;17).. Medical oncology (Northwood, London, England). 29(3):2095-101. Abstract
Clinical Research Division
Pullarkat V, Slovak ML, Kopecky KJ, Forman SJ, Appelbaum FR.  2008.  Impact of cytogenetics on the outcome of adult acute lymphoblastic leukemia: results of Southwest Oncology Group 9400 study.. Blood. 111(5):2563-72. Abstract
Chauncey TR, Gundacker H, Shadman M, List AF, Dakhil SR, Erba HP, Slovak ML, Chen I-M, Willman CL, Kopecky KJ et al..  2010.  Sequential phase II Southwest Oncology Group studies (S0112 and S0301) of daunorubicin and cytarabine by continuous infusion, without and with ciclosporin, in older patients with previously untreated acute myeloid leukaemia.. British journal of haematology. 148(1):48-58. Abstract